Show simple item record

dc.contributor.authorCurtis, Den_US
dc.date.accessioned2018-09-27T12:32:46Z
dc.date.available2018-03-26en_US
dc.date.issued2018-08en_US
dc.date.submitted2018-04-23T10:35:52.877Z
dc.identifier.other10.1097/YPG.0000000000000197
dc.identifier.urihttp://qmro.qmul.ac.uk/xmlui/handle/123456789/45464
dc.description.abstractBACKGROUND: The polygenic risk score (PRS) is derived from single nucleotide polymorphisms (SNPs) including those that are genome-wide significant and also including a large number of others more weakly associated with schizophrenia. Such variants are widely dispersed, though concentrated near genes expressed in the brain, and it has been proposed that these SNP associations result from impacts on cell regulatory networks that ultimately affect the expression or function of a modest number of 'core' genes. A previous study showed association of some genome-wide association study-significant variants with expression of a number of genes, by examining pairwise correlations of gene expression with SNP genotypes. METHODS: The present study used data downloaded from the CommonMind Consortium site, consisting of SNP genotypes and RNAseq expression data from the dorsolateral prefrontal cortex, to examine whether the expression of individual genes or sets of genes correlated with PRS in 207 controls and 209 schizophrenia cases. RESULTS: Although the PRS was significantly associated with phenotype, the correlations with genes and gene sets followed distributions expected by chance. Thus, this analysis failed to show that the PRS captures a cumulative effect of multiple variants impacting the expression of a small number of genes and it failed to focus attention on a small number of genes of biological relevance. CONCLUSION: The multiple SNP associations observed in schizophrenia may result from other mechanisms, including effects mediated indirectly through environmental risk factors.en_US
dc.description.sponsorshipThe CommonMind Consortium data generation was supported by funding from Takeda Pharmaceuticals Company Limited, F. Hoffman-La Roche Ltd and NIH grants R01MH085542, R01MH093725, P50MH066392, P50MH080405, R01MH097276, RO1-MH075916, P50M096891, P50MH084053S1, R37MH057881 and R37MH057881S1, HHSN271201300031C, AG02219, AG05138 and MH06692en_US
dc.format.extent59 - 65en_US
dc.languageengen_US
dc.language.isoenen_US
dc.relation.ispartofPsychiatr Geneten_US
dc.rightsAll rights reserved
dc.subjectCase-Control Studiesen_US
dc.subjectGenetic Predisposition to Diseaseen_US
dc.subjectGenome-Wide Association Studyen_US
dc.subjectHumansen_US
dc.subjectMultifactorial Inheritanceen_US
dc.subjectPolymorphism, Single Nucleotideen_US
dc.subjectPrefrontal Cortexen_US
dc.subjectRegression Analysisen_US
dc.subjectSchizophreniaen_US
dc.titlePolygenic risk score for schizophrenia is not strongly associated with the expression of specific genes or gene sets.en_US
dc.typeArticle
dc.rights.holderWolters Kluwer Health
dc.identifier.doi10.1097/YPG.0000000000000197en_US
pubs.author-urlhttps://www.ncbi.nlm.nih.gov/pubmed/29672343en_US
pubs.issue4en_US
pubs.notesNo embargoen_US
pubs.publication-statusPublisheden_US
pubs.volume28en_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record